CALMINO GROUP AB AND IMMURON LIMITED JOIN THE TREAMENT OF SYMPTOMS OF IRRITABLE BOWEL SYNDROME (IBS)
Gothenburg, Sweden, 11th of March, 2024
Calmino group AB (Göteborg, Sweden) and Immuron Limited (Melbourne, Australia, ASX: IMC; NASDAQ: IMRN) have entered an exclusive distribution agreement for the territory of Australia and New Zealand to launch ProIBS® for the treatment of symptoms related to IBS. This is a collaborative fee free agreement that includes all marketing and sales activities of ProIBS® and is in effect immediately.
Immuron Limited is an Australian based and globally integrated biopharmaceutical company focused on digestive health. ProIBS®will join the portfolio along with the rapidly growing Travelan® brand to build on the premium efficacy portfolio that will deliver better outcomes for consumers.
“The Calmino team is happy to work with a well-established, experienced, and professional company like Immuron. We see Australia and New Zealand as important Asian Pacific markets with significant potential.”
Tobias Kisker, CEO and founder of Calmino group AB
“Following the rapid growth of Travelan® in pharmacy as the leading product for the prevention of traveller’s diarrhoea, we have identified a great opportunity with ProIBS® to further expand our digestive health portfolio by providing pharmacists a proven premium efficacy product that delivers unique benefits to their customers. With ProIBS®, we are able to provide an innovative and European certified medical device for the treatment of symptoms related to IBS. The product has been on the Swedish pharmacy market for more than a decade. Because it is backed by science and recommended by physicians and dietitians, we can promote ProIBS® with absolute confidence. We are looking forward to offering a solution that truly improves the liveability of the affected people.“
Flavio Palumbo, Chief Commercial Officer of Immuron Limited
IRRITABLE BOWEL SYNDROME (IBS)
IBS affects around 10% of the population worldwide, less than 2% are diagnosed. It is a chronic disorder characterised by a group of symptoms that occur at the same time, including repeated abdominal pain and changes in bowel movements, which may be diarrhea, constipation, or both. The main cause of IBS is not definitely known therefore the treatment focuses on the symptoms.
ProIBS® – TO HELP PATIENTS FOR THE TREATMENT OF IBS SYMPTOMS
ProIBS® in Europe is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and changed bowel movements (diarrhoea and/or constipation).
To learn more about ProIBS®, visit https://proibs.eu/
Looking for new products to present in your market? Can you help us enter a new market? Our goal is to maintain constant growth based on expansion into new markets and an improved presence in current markets. Should you see an opportunity for our collaboration, please do not hesitate to contact us!
Grow your business by becoming our official business partner!
